$RVNC
Revance Therapeutics, Inc. Stock $rvnc

$rvnc Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000147929024000038 Filed on February 28, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$51.94M	$69.80M	$234.0M
YoY Change	5.28%	39.82%	76.55%
Cost Of Revenue	$14.91M	$17.47M	$74.36M
YoY Change	-7.79%	-25.7%	43.93%
Gross Profit	$37.03M	$52.33M	$159.7M
YoY Change	11.66%	98.16%	97.38%
Gross Profit Margin	71.29%	74.97%	68.23%
Selling, General & Admin	$68.91M	$84.30M	$297.7M
YoY Change	4.4%	32.66%	32.96%
% of Gross Profit	186.13%	161.09%	186.46%
Research & Development	$14.39M	$20.05M	$79.41M
YoY Change	-37.9%	2.6%	-21.6%
% of Gross Profit	38.87%	38.31%	49.73%
Depreciation & Amortization	$1.981M	-$899.0K	$11.38M
YoY Change	-70.07%	-105.15%	-66.28%
% of Gross Profit	5.35%	-1.72%	7.12%
Operating Expenses	$83.31M	$105.4M	$377.1M
YoY Change	-6.59%	4.36%	15.97%
Operating Profit	-$46.83M	-$53.11M	-$316.8M
YoY Change	-19.31%	-28.83%	-7.36%
Interest Expense	$5.256M	-$1.964M	$19.36M
YoY Change	16.88%	-858.3%	17.49%
% of Operating Profit
Other Income/Expense, Net	-$438.0K	$218.0K	-$838.0K
YoY Change	87.18%	-112.11%	-61.58%
Pretax Income	-$49.53M	-$55.70M	-$323.7M
YoY Change	-17.17%	-61.84%	-9.01%
Income Tax		$0.00	$300.0K
% Of Pretax Income
Net Earnings	-$53.20M	-$55.70M	-$324.0M
YoY Change	-11.04%	-61.84%	-9.09%
Net Earnings / Revenue	-102.43%	-79.8%	-138.44%
Basic Earnings Per Share	-$0.58		-$3.83
Diluted Earnings Per Share	-$0.58	-$0.64	-$3.83
COMMON SHARES
Basic Shares Outstanding	88.21M shares	87.81M shares	84.60M shares
Diluted Shares Outstanding	91.92M shares		84.60M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$277.1M	$253.9M	$253.9M
YoY Change	1.14%	-25.47%	-25.47%
Cash & Equivalents	$132.6M	$137.3M	$137.3M
Short-Term Investments	$144.5M	$116.6M	$116.6M
Other Short-Term Assets	$12.45M	$11.70M	$11.70M
YoY Change	110.01%	168.48%	168.48%
Inventory	$50.28M	$45.58M	$45.58M
Prepaid Expenses
Receivables	$29.89M	$27.68M	$27.68M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$369.7M	$338.9M	$338.9M
YoY Change	14.45%	-9.57%	-9.57%
LONG-TERM ASSETS
Property, Plant & Equipment	$17.51M	$17.23M	$90.21M
YoY Change	25.46%	-22.2%	33.14%
Goodwill		$0.00
YoY Change		-100.0%
Intangibles	$8.725M	$9.808M
YoY Change	-72.06%	-63.68%
Long-Term Investments
YoY Change
Other Assets	$217.0K	$321.0K	$39.57M
YoY Change	-89.53%	-80.97%	12.3%
Total Long-Term Assets	$138.4M	$139.6M	$139.6M
YoY Change	-38.41%	-32.62%	-32.62%
TOTAL ASSETS
Total Short-Term Assets	$369.7M	$338.9M	$338.9M
Total Long-Term Assets	$138.4M	$139.6M	$139.6M
Total Assets	$508.1M	$478.5M	$478.5M
YoY Change	-7.24%	-17.78%	-17.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.276M	$13.81M	$13.81M
YoY Change	-59.4%	203.76%	203.76%
Accrued Expenses	$40.31M	$53.82M	$56.34M
YoY Change	12.4%	-9.32%	-1.22%
Deferred Revenue	$9.784M	$10.74M
YoY Change	62.09%	56.36%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$5.000M	$2.500M	$5.151M
YoY Change	-73.13%	273.69%	669.96%
Total Short-Term Liabilities	$68.90M	$89.22M	$89.22M
YoY Change	-11.65%	17.89%	17.89%
LONG-TERM LIABILITIES
Long-Term Debt	$424.8M	$426.6M	$426.6M
YoY Change	11.84%	12.45%	12.45%
Other Long-Term Liabilities	$2.835M	$2.835M	$114.2M
YoY Change	0.0%	90.91%	0.0%
Total Long-Term Liabilities	$427.7M	$429.4M	$540.8M
YoY Change	14985.47%	28817.85%	9.57%
TOTAL LIABILITIES
Total Short-Term Liabilities	$68.90M	$89.22M	$89.22M
Total Long-Term Liabilities	$427.7M	$429.4M	$540.8M
Total Liabilities	$606.8M	$630.1M	$630.1M
YoY Change	5.63%	10.67%	10.67%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.100B	-$2.100B
YoY Change	16.67%	16.67%
Common Stock	$2.033B	$1.927B
YoY Change	13.72%	9.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$98.67M	-$151.6M	-$151.6M
YoY Change
Total Liabilities & Shareholders Equity	$508.1M	$478.5M	$478.5M
YoY Change	-7.24%	-17.78%	-17.78%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$53.20M	-$55.70M	-$324.0M
YoY Change	-11.04%	-61.84%	-9.09%
Depreciation, Depletion And Amortization	$1.981M	-$899.0K	$11.38M
YoY Change	-70.07%	-105.15%	-66.28%
Cash From Operating Activities	-$65.94M	-$42.73M	-$216.6M
YoY Change	-5.12%	41.58%	11.9%
INVESTING ACTIVITIES
Capital Expenditures	$1.712M	$1.779M	$6.886M
YoY Change	96.78%	38.12%	114.52%
Acquisitions
YoY Change
Other Investing Activities	-$30.00M	$4.149M	$116.6M
YoY Change	-131.19%	-90.18%	-186.01%
Cash From Investing Activities	-$31.71M	$2.370M	$109.7M
YoY Change	-133.27%	-94.21%	-179.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$100.2M
YoY Change			214.9%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$92.83M	-1.629M	$136.6M
YoY Change	2743.12%	-73.61%	-58.83%
NET CHANGE
Cash From Operating Activities	-$65.94M	-42.73M	-$216.6M
Cash From Investing Activities	-$31.71M	2.370M	$109.7M
Cash From Financing Activities	$92.83M	-1.629M	$136.6M
Net Change In Cash	-$4.820M	-41.99M	$29.73M
YoY Change	-116.57%	-1011.83%	-4660.12%
FREE CASH FLOW
Cash From Operating Activities	-$65.94M	-$42.73M	-$216.6M
Capital Expenditures	$1.712M	$1.779M	$6.886M
Free Cash Flow	-$67.65M	-$44.51M	-$223.5M
YoY Change	-3.86%	41.44%	13.57%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	2045000	usd
CY2023	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	550817000	usd
CY2022	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	474523000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-316777000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-341958000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-274676000	usd
CY2023	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	13285000	usd
CY2022	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	4891000	usd
CY2021	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	337000	usd
CY2022	us-gaap	Interest Expense InterestExpense	16474000	usd
CY2021	us-gaap	Interest Expense InterestExpense	6273000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-698000	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001479290
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2020	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2023#AccountingStandardsUpdate202006Member
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-36297
CY2023	dei	Entity Registrant Name EntityRegistrantName	Revance Therapeutics, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0551645
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	1222 Demonbreun Street, Suite 2000
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Nashville
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	TN
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	37203
CY2023	dei	City Area Code CityAreaCode	615
CY2023	dei	Local Phone Number LocalPhoneNumber	724-7755
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023	dei	Trading Symbol TradingSymbol	RVNC
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	2200000000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	88214054	shares
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	238
CY2023	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2023	dei	Auditor Location AuditorLocation	San Jose, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	137329000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	108965000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	550000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	0	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	116586000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	231742000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	27676000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11339000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	45579000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	18325000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11145000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4356000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	338865000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	374727000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17225000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13799000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	0	usd
CY2022Q4	us-gaap	Goodwill Goodwill	77175000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	9808000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	35344000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	53167000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	39223000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	19815000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	6393000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	6870000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	6052000	usd
CY2023Q4	rvnc	Finance Lease Prepaid Expense Noncurrent FinanceLeasePrepaidExpenseNoncurrent	32383000	usd
CY2022Q4	rvnc	Finance Lease Prepaid Expense Noncurrent FinanceLeasePrepaidExpenseNoncurrent	27500000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	321000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1687000	usd
CY2023Q4	us-gaap	Assets Assets	478454000	usd
CY2022Q4	us-gaap	Assets Assets	581900000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	13809000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4546000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	53824000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6867000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2651000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	59357000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	10737000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	669000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5703000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4243000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2500000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	89224000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	75682000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	426595000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	379374000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	70419000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	78577000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	40985000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	34182000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2835000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1485000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	630058000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	569300000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	190000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	190000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	87962765	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	87962765	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	82385810	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	82385810	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	88000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	82000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1926654000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1767266000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	14000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-374000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2078360000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1754374000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-151604000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	12600000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	478454000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	581900000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	234040000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	132565000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	77798000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	297732000	usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	16007000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	223934000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	198821000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	79410000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	101286000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	116255000	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	77175000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	69789000	usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2021	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6130000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	27847000	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	13988000	usd
CY2021	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	352474000	usd
CY2023	us-gaap	Interest Expense InterestExpense	19356000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-838000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2181000	usd
CY2023	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-323686000	usd
CY2022	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-355722000	usd
CY2021	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-281310000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	300000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	700000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-323986000	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	388000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-356000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-323598000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-356778000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-281328000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-323986000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-323986000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-356422000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-356422000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-281310000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-281310000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.83
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.83
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.90
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.90
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.17
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.17
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	84599409	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	84599409	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	72713340	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	72713340	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	67507818	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	67507818	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	374290000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	12923000	usd
CY2021	rvnc	Stock Issued During Period Value Restricted Stock Award Net Of Shares Repurchased StockIssuedDuringPeriodValueRestrictedStockAwardNetOfSharesRepurchased	0	usd
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3765000	usd
CY2021	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	8185000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	44310000	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-18000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-281310000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	68471000	usd
CY2022	rvnc	Stock Issued During Period Value New Issues Follow On Offering Net Of Underwriting Discounts Commissions And Offering Cost StockIssuedDuringPeriodValueNewIssuesFollowOnOfferingNetOfUnderwritingDiscountsCommissionsAndOfferingCost	215861000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	31586000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3856000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	964000	usd
CY2022	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	6496000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	54788000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-356000	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	348000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-356422000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	12600000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	99959000	usd
CY2023	rvnc	Stock Issued During Period Value Restricted Stock Award Net Of Shares Repurchased StockIssuedDuringPeriodValueRestrictedStockAwardNetOfSharesRepurchased	0	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	11609000	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3681000	usd
CY2023	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	8216000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	52331000	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	388000	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	30000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-323986000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-151604000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-323986000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-356422000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-281310000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	93182000	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	69789000	usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	47813000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	52340000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	43434000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11375000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	33732000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	19853000	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2397000	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1880000	usd
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1250000	usd
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	2318000	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	5414000	usd
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	0	usd
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	6438000	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2176000	usd
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-89000	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-646000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1230000	usd
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	80000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	16338000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	7990000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1519000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	14910000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6008000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4278000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6789000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3596000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1751000	usd
CY2023	rvnc	Increase Decreasein Operating Lease Rightof Use Assets IncreaseDecreaseinOperatingLeaseRightofUseAssets	36399000	usd
CY2022	rvnc	Increase Decreasein Operating Lease Rightof Use Assets IncreaseDecreaseinOperatingLeaseRightofUseAssets	6691000	usd
CY2021	rvnc	Increase Decreasein Operating Lease Rightof Use Assets IncreaseDecreaseinOperatingLeaseRightofUseAssets	14708000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-900000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	602000	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-333000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6900000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-5448000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1824000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-5025000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	15564000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	6825000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-4288000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	1930000	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1631000	usd
CY2023	rvnc	Increase Decreasein Operating Lease Liabilities IncreaseDecreaseinOperatingLeaseLiabilities	30717000	usd
CY2022	rvnc	Increase Decreasein Operating Lease Liabilities IncreaseDecreaseinOperatingLeaseLiabilities	6314000	usd
CY2021	rvnc	Increase Decreasein Operating Lease Liabilities IncreaseDecreaseinOperatingLeaseLiabilities	12294000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	1350000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	1485000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-216575000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-193548000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-221538000	usd
CY2023	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	385432000	usd
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	232178000	usd
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	172000000	usd
CY2023	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	263923000	usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	347966000	usd
CY2021	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	183590000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6886000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3210000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10375000	usd
CY2023	rvnc	Prepayments For A Finance Lease PrepaymentsForAFinanceLease	4883000	usd
CY2022	rvnc	Prepayments For A Finance Lease PrepaymentsForAFinanceLease	19800000	usd
CY2021	rvnc	Prepayments For A Finance Lease PrepaymentsForAFinanceLease	7700000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	109740000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-138798000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-29665000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	100183000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	31814000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	21706000	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	48415000	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	98150000	usd
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	15289000	usd
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	8216000	usd
CY2023	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	849000	usd
CY2021	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	340000	usd
CY2023	rvnc	Proceeds From Issuance Of Common Stock In Connection With Follow On Offering Net Of Discounts And Commissions ProceedsFromIssuanceOfCommonStockInConnectionWithFollowOnOfferingNetOfDiscountsAndCommissions	0	usd
CY2022	rvnc	Proceeds From Issuance Of Common Stock In Connection With Follow On Offering Net Of Discounts And Commissions ProceedsFromIssuanceOfCommonStockInConnectionWithFollowOnOfferingNetOfDiscountsAndCommissions	216200000	usd
CY2021	rvnc	Proceeds From Issuance Of Common Stock In Connection With Follow On Offering Net Of Discounts And Commissions ProceedsFromIssuanceOfCommonStockInConnectionWithFollowOnOfferingNetOfDiscountsAndCommissions	0	usd
CY2023	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	usd
CY2022	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	348000	usd
CY2021	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	136567000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	331694000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	29869000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	29732000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-652000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-221334000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	115017000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	115669000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	337003000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	144749000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	115017000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	115669000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	15090000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	12231000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	5031000	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	300000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	700000	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-324000000.0	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2100000000	usd
CY2023Q4	rvnc	Working Capital Surplus WorkingCapitalSurplus	249600000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	253900000	usd
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></div>At the beginning of 2023, we changed our presentation of internal-use software where approximately $8.3 million has been reclassified from property and equipment, net into intangible assets, net. This reclassification has no impact on net loss or cash flows.
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13799000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	35344000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities in the consolidated financial statements and accompanying notes. These estimates form the basis for judgments we make about the carrying values of our assets and liabilities, which are not readily apparent from other sources. We base our estimates and judgments on historical information and on various other assumptions that we believe are reasonable under the circumstances. GAAP requires us to make estimates and judgments in several areas, including, but not limited to, the incremental borrowing rate used to measure lease liabilities, the recoverability of goodwill and long-lived assets, useful lives associated with property and equipment and intangible assets, the period of benefit associated with deferred costs, revenue recognition (including the timing of satisfaction of performance obligations, estimating variable consideration, estimating stand-alone selling prices of promised goods and services, and allocation of transaction price to performance obligations), deferred revenue classification, valuation and assumptions underlying stock-based compensation and income taxes.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of issuance of these consolidated financial statements, we are not aware of any specific event or circumstance that would require us to update our estimates, judgments or revise the carrying value of our assets or liabilities. These estimates may change as new events occur and additional information is obtained, and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to our consolidated financial statements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of the Macroeconomic Environment on our Business</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. and global financial markets have experienced significant volatility in recent years, which has led to disruptions to commerce and pricing stability, impacts to foreign exchange rates, labor shortages, global inflation, higher interest rates and supply chain disruptions. Due to current inflationary pressures, we have experienced higher costs throughout our business, which we expect may continue during 2024. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ultimate impact of the current and anticipated global economic conditions is highly uncertain and we do not yet know the full extent of potential delays or impacts on our regulatory process, our manufacturing operations, supply chain, end user demand for our Products, commercialization efforts, business operations, clinical trials and other aspects of our business and the aesthetics industry, the healthcare systems or the global economy as a whole.</span></div>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Business Risk</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a limited number of third-party suppliers for the manufacturing of DAXXIFY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In particular, we outsource the manufacture of bulk peptide through an agreement with a single supplier, and we currently primarily manufacture DAXXIFY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> commercial drug product supply through ABPS. To decrease the risk of an interruption to our drug supply, we maintain an inventory of peptide. In addition, we plan to utilize the PCI facility, if approved, for the clinical and commercial production of DAXXIFY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> drug product. However, if and until the PCI facility is approved, we are dependent on the ABPS facility. If ABPS or the bulk peptide supplier is unable to fulfill its manufacturing obligations for any reason, such an event could make it difficult or, in certain cases, impossible for us to continue to manufacture our drug product and/or drug substance for a substantial period of time.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product revenue relies on one third-party distributor for our products.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to a concentration of credit risk consist of short-term investments. Under our investment policy, we limit our credit exposure by investing in highly liquid funds and debt obligations of the U.S. government and its agencies with high credit quality. Our cash, cash equivalents, and short-term investments are held in the U.S. Such deposits may, at times, exceed federally insured limits. We have not experienced any significant losses on our deposits of cash, cash equivalents, and short-term investments.</span></div>
CY2023Q4	rvnc	Number Of Third Party Distributors For Each Product NumberOfThirdPartyDistributorsForEachProduct	1	distributor
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	7400000	usd
CY2023Q4	rvnc	Restricted Cash Minimum Balance RestrictedCashMinimumBalance	800000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	6100000	usd
CY2022Q4	rvnc	Restricted Cash Minimum Balance RestrictedCashMinimumBalance	700000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1000000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	100000	usd
CY2023	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	16000000	usd
CY2022Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	69800000	usd
CY2023	us-gaap	Advertising Expense AdvertisingExpense	8400000	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	5100000	usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense	6200000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	234040000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	132565000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	77798000	usd
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	41000000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	84739000	usd
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	9133000	usd
CY2023	rvnc	Contract With Customer Liability Billings And Adjustments Net ContractWithCustomerLiabilityBillingsAndAdjustmentsNet	4666000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	80272000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	225842000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	30000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	16000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	225856000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	321802000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	374000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	321428000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	225856000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	321428000	usd
CY2022Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	69800000	usd
CY2023Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	147000000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	146964000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	69789000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	77175000	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	77175000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	0	usd
CY2023Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	67752000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	41937000	usd
CY2023Q4	rvnc	Finite Lived Intangible Assets Accumulated Impairment Loss FiniteLivedIntangibleAssetsAccumulatedImpairmentLoss	16007000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	9808000	usd
CY2022Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	90637000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	55293000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	35344000	usd
CY2022	rvnc	Finance Lease Right Of Use Asset Amortization Including Amount Capitalized To Inventory FinanceLeaseRightOfUseAssetAmortizationIncludingAmountCapitalizedToInventory	5414000	usd
CY2021	rvnc	Finance Lease Right Of Use Asset Amortization Including Amount Capitalized To Inventory FinanceLeaseRightOfUseAssetAmortizationIncludingAmountCapitalizedToInventory	0	usd
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1402000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6130000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	25756000	usd
CY2023	rvnc	Amortization Expense Selling General And Administrative AmortizationExpenseSellingGeneralAndAdministrative	2998000	usd
CY2022	rvnc	Amortization Expense Selling General And Administrative AmortizationExpenseSellingGeneralAndAdministrative	3640000	usd
CY2023	rvnc	Amortization Expense Research And Development AmortizationExpenseResearchAndDevelopment	283000	usd
CY2022	rvnc	Amortization Expense Research And Development AmortizationExpenseResearchAndDevelopment	311000	usd
CY2023	us-gaap	Adjustment For Amortization AdjustmentForAmortization	9411000	usd
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization	29707000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2569000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2332000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2181000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2181000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	545000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9808000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3938000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	505000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	17418000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	4933000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	24223000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	12887000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	45579000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	18325000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	31132000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	28014000	usd
CY2023Q4	rvnc	Selling General And Administrative Accrued SellingGeneralAndAdministrativeAccrued	9019000	usd
CY2022Q4	rvnc	Selling General And Administrative Accrued SellingGeneralAndAdministrativeAccrued	9681000	usd
CY2023Q4	rvnc	Research And Development Accrual ResearchAndDevelopmentAccrual	5173000	usd
CY2022Q4	rvnc	Research And Development Accrual ResearchAndDevelopmentAccrual	9012000	usd
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1919000	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	5113000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1919000	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1912000	usd
CY2023Q4	rvnc	Accrued Inventory Current AccruedInventoryCurrent	1478000	usd
CY2022Q4	rvnc	Accrued Inventory Current AccruedInventoryCurrent	2312000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3184000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3313000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	53824000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	59357000	usd
CY2023Q4	rvnc	Lessee Operating Lease Number Of Renewal Options LesseeOperatingLeaseNumberOfRenewalOptions	1	option_to_extend_lease_term
CY2017Q1	rvnc	Purchase Obligation Period Required For Written Notice Of Termination PurchaseObligationPeriodRequiredForWrittenNoticeOfTermination	P18M
CY2021Q4	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	30000000	usd
CY2021Q4	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	30000000	usd
CY2021Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	30000000	usd
CY2022Q2	rvnc	Purchase Obligation Eliminated Year Two PurchaseObligationEliminatedYearTwo	30000000	usd
CY2022Q2	rvnc	Purchase Obligation Eliminated Year Three PurchaseObligationEliminatedYearThree	30000000	usd
CY2022Q2	rvnc	Purchase Obligation Eliminated Year One PurchaseObligationEliminatedYearOne	30000000	usd
CY2023Q1	rvnc	Purchase Obligation Eliminated Year One PurchaseObligationEliminatedYearOne	23900000	usd
CY2023	rvnc	Finance Lease Right Of Use Asset Amortization Including Amount Capitalized To Inventory FinanceLeaseRightOfUseAssetAmortizationIncludingAmountCapitalizedToInventory	9034000	usd
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	2687000	usd
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	0	usd
CY2023	rvnc	Finance Lease Variable Cost FinanceLeaseVariableCost	682000	usd
CY2022	rvnc	Finance Lease Variable Cost FinanceLeaseVariableCost	2182000	usd
CY2021	rvnc	Finance Lease Variable Cost FinanceLeaseVariableCost	0	usd
CY2023	rvnc	Total Finance Lease Costs TotalFinanceLeaseCosts	11118000	usd
CY2022	rvnc	Total Finance Lease Costs TotalFinanceLeaseCosts	10283000	usd
CY2021	rvnc	Total Finance Lease Costs TotalFinanceLeaseCosts	0	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	12434000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	8881000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	8026000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	2225000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	1628000	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	1490000	usd
CY2023	rvnc	Total Operating Lease Costs TotalOperatingLeaseCosts	14659000	usd
CY2022	rvnc	Total Operating Lease Costs TotalOperatingLeaseCosts	10509000	usd
CY2021	rvnc	Total Operating Lease Costs TotalOperatingLeaseCosts	9516000	usd
CY2023	us-gaap	Lease Cost LeaseCost	25777000	usd
CY2022	us-gaap	Lease Cost LeaseCost	20792000	usd
CY2021	us-gaap	Lease Cost LeaseCost	9516000	usd
CY2023Q4	rvnc	Accounts Payable Finance Leases Current AccountsPayableFinanceLeasesCurrent	2200000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	2659000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	10172000	usd
CY2023Q4	rvnc	Lease Liability To Be Payment Due Year One LeaseLiabilityToBePaymentDueYearOne	12831000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	10854000	usd
CY2023Q4	rvnc	Lease Liability To Be Payment Due Year Two LeaseLiabilityToBePaymentDueYearTwo	10854000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	11185000	usd
CY2023Q4	rvnc	Lease Liability To Be Payment Due Year Three LeaseLiabilityToBePaymentDueYearThree	11185000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	4536000	usd
CY2023Q4	rvnc	Lease Liability To Be Payment Due Year Four LeaseLiabilityToBePaymentDueYearFour	4536000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	4021000	usd
CY2023Q4	rvnc	Lease Liability To Be Payment Due Year Five LeaseLiabilityToBePaymentDueYearFive	4021000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	24565000	usd
CY2023Q4	rvnc	Lease Liability Payments Due After Year Five LeaseLiabilityPaymentsDueAfterYearFive	24565000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	2659000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	65333000	usd
CY2023Q4	rvnc	Lease Liability To Be Payment Due LeaseLiabilityToBePaymentDue	67992000	usd
CY2023Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	8000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	18645000	usd
CY2023Q4	rvnc	Lease Liability Undiscounted Excess Amount LeaseLiabilityUndiscountedExcessAmount	18653000	usd
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	2651000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	46688000	usd
CY2023Q4	rvnc	Lease Liability LeaseLiability	49339000	usd
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y2M12D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y1M6D
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.107
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.100
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	12078000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	8320000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	10405000	usd
CY2023	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	1404000	usd
CY2022	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	2687000	usd
CY2021	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	0	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	18255000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	11097000	usd
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	22694000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	18854000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	22456000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	11808000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	usd
CY2021Q2	rvnc	Collaborative Agreement Number Of Extension Periods CollaborativeAgreementNumberOfExtensionPeriods	1	option_to_extend_lease_term
CY2023Q4	us-gaap	Other Commitment Due In Next Twelve Months OtherCommitmentDueInNextTwelveMonths	18400000	usd
CY2023Q4	us-gaap	Other Commitment Due In Second Year OtherCommitmentDueInSecondYear	19700000	usd
CY2023Q4	us-gaap	Other Commitment Due In Third Year OtherCommitmentDueInThirdYear	25300000	usd
CY2023Q4	us-gaap	Other Commitment Due In Fourth Year OtherCommitmentDueInFourthYear	29500000	usd
CY2023Q4	us-gaap	Other Commitment Due In Fifth Year OtherCommitmentDueInFifthYear	29500000	usd
CY2023Q4	us-gaap	Other Commitment Due After Fifth Year OtherCommitmentDueAfterFifthYear	105000000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	429095000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	379374000	usd
CY2023	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	15137000	usd
CY2022	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	11855000	usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1791000	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1662000	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	606000	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	270000	usd
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	17534000	usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	13787000	usd
CY2020Q1	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	28900000	usd
CY2020Q1	rvnc	Capped Calls Price Cap CappedCallsPriceCap	48.88
CY2020Q1	rvnc	Capped Calls Premium Percentage Over Sale Price CappedCallsPremiumPercentageOverSalePrice	1
CY2020Q1	rvnc	Capped Calls Number Of Shares Subject To Anti Dilution Adjustments CappedCallsNumberOfSharesSubjectToAntiDilutionAdjustments	8900000	shares
CY2020Q1	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	28900000	usd
CY2023	rvnc	Numberof Equity Compensation Plans NumberofEquityCompensationPlans	4	equity_compensation_plan
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4929097	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.78
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	213948	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	33.49
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	708084	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	16.39
CY2023Q4	rvnc	Sharebased Compensation Arrangementby Sharebased Payment Award Options Exercised Aggregate Intrinsic Value SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisedAggregateIntrinsicValue	668000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	601611	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	28.87
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3833350	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.75
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y6M
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	732000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	3231263	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	3231263	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	19.08
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y1M6D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	717000	usd
CY2022Q4	rvnc	Sharebased Compensation Arrangementby Sharebased Payment Award Options Exercised Aggregate Intrinsic Value SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisedAggregateIntrinsicValue	2400000	usd
CY2021Q4	rvnc	Sharebased Compensation Arrangementby Sharebased Payment Award Options Exercised Aggregate Intrinsic Value SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisedAggregateIntrinsicValue	3600000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	20.40
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.64
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	15.38
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	49187000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	52340000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	43434000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	3144000	usd
CY2022	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	2448000	usd
CY2021	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	876000	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	52331000	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	54788000	usd
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	44310000	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	6519000	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	55941000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M18D
CY2023Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	219200000	usd
CY2022Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	288200000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	300000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	700000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	300000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	700000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-68037000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-74849000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-59075000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-9467000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1678000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1489000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	2862000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	4750000	usd
CY2023Q4	rvnc	Deferred Tax Assets Interest Limitation DeferredTaxAssetsInterestLimitation	3918000	usd
CY2022Q4	rvnc	Deferred Tax Assets Interest Limitation DeferredTaxAssetsInterestLimitation	3486000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	3629000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1171000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	24000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	26000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	514207000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	439151000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1863000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1534000	usd
CY2023	rvnc	Effective Income Tax Rate Reconciliation Employee Retention Credit Amount EffectiveIncomeTaxRateReconciliationEmployeeRetentionCreditAmount	1555000	usd
CY2022	rvnc	Effective Income Tax Rate Reconciliation Employee Retention Credit Amount EffectiveIncomeTaxRateReconciliationEmployeeRetentionCreditAmount	0	usd
CY2021	rvnc	Effective Income Tax Rate Reconciliation Employee Retention Credit Amount EffectiveIncomeTaxRateReconciliationEmployeeRetentionCreditAmount	0	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	57902000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	57582000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	57086000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses	16207000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses	14656000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses	0	usd
CY2023	rvnc	Effective Income Tax Rate Reconciliation Non Deductible Executive Compensation EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensation	9225000	usd
CY2022	rvnc	Effective Income Tax Rate Reconciliation Non Deductible Executive Compensation EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensation	4155000	usd
CY2021	rvnc	Effective Income Tax Rate Reconciliation Non Deductible Executive Compensation EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensation	2352000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	800000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	591000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	233000	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	300000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	553000	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	0	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-2213000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-1803000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-551000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	300000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	700000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	377138000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	333638000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	38600000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	29195000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	29849000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	18690000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	19220000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	19051000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	14553000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	6510000	usd
CY2023Q4	rvnc	Deferred Tax Asset Lease Arrangements DeferredTaxAssetLeaseArrangements	12543000	usd
CY2022Q4	rvnc	Deferred Tax Asset Lease Arrangements DeferredTaxAssetLeaseArrangements	9979000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	10126000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	12655000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	4607000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	495654000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	427507000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	18553000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	11644000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	18553000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	11644000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	18553000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	11644000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	68100000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	71900000	usd
CY2023Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9709000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	7754000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	7166000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	1598000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	916000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1590000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1039000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	588000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	12897000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9709000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	7754000	usd
CY2023	rvnc	Indemnification Liability Recordedduring Period IndemnificationLiabilityRecordedduringPeriod	0	usd
CY2022	rvnc	Indemnification Liability Recordedduring Period IndemnificationLiabilityRecordedduringPeriod	0	usd
CY2022Q4	rvnc	Number Of Alleged Patent Infringements NumberOfAllegedPatentInfringements	3	patent
CY2023Q4	us-gaap	Litigation Reserve LitigationReserve	0	usd
CY2022Q4	us-gaap	Litigation Reserve LitigationReserve	0	usd
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	234040000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	132565000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	77798000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-316777000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-341958000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-274676000	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001479290-24-000038-index-headers.html	Edgar Link	pending
0001479290-24-000038-index.html	Edgar Link	pending
0001479290-24-000038.txt	Edgar Link	pending
0001479290-24-000038-xbrl.zip	Edgar Link	pending
ex_1032xmanagementbonuspla.htm	Edgar Link	pending
ex_211listofsubsidiariesxf.htm	Edgar Link	pending
ex_231xpublicaccountingfir.htm	Edgar Link	pending
ex_311xcertificationofpeox.htm	Edgar Link	pending
ex_312xcertificationofpfox.htm	Edgar Link	pending
ex_321xcertificationofpeox.htm	Edgar Link	pending
ex_322xcertificationofpfox.htm	Edgar Link	pending
ex_44xdescriptionsofsecuri.htm	Edgar Link	pending
ex_971xincentivecompensati.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
rvnc-20231231.htm	Edgar Link	pending
rvnc-20231231.xsd	Edgar Link	pending
rvnc-20231231_g1.jpg	Edgar Link	pending
Show.js	Edgar Link	pending
rvnc-20231231_cal.xml	Edgar Link	unprocessable
rvnc-20231231_def.xml	Edgar Link	unprocessable
rvnc-20231231_lab.xml	Edgar Link	unprocessable
rvnc-20231231_pre.xml	Edgar Link	unprocessable
rvnc-20231231_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RVNC
Revance Therapeutics, Inc. Stock $rvnc

2024 Q1 Form 10-K Financial Statement

#000147929024000038 Filed on February 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RVNC Revance Therapeutics, Inc. Stock $rvnc

2024 Q1 Form 10-K Financial Statement

#000147929024000038 Filed on February 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RVNC
Revance Therapeutics, Inc. Stock $rvnc